semaglutide cardiovascular outcomes news 2025 Lower risk of events in patients initiated on 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular in People with Overweight or Obesity in Oral Semaglutide and Cardiovascular Outcomes

Flavoring agents, though generally recognized as safe for ingestion, can become highly toxic upon inhalation following thermal degradation

Make sure your provider knows the exact strength, form and frequency of your compounded medication so they can make a safe comparison to the brand-name product

Key physiological impacts include: Increased work of breathing due to chest wall mass Reduced lung compliance and diaphragmatic excursion Decreased functional residual capacity and expiratory reserve volume Higher metabolic demands requiring increased respiratory effort Obesity is also strongly associated with obstructive sleep apnoea (OSA), a condition where breathing repeatedly stops during sleep, further compromising respiratory function and contributing to daytime breathlessness

Though in recent years there has been increased communication between DMHC and providers about these struggles, there is still much room for improvement

Its an incredibly frustrating paradox for researchers and health professionals alike

Nature 465 , 487491 (2010)